Next Article in Journal
Optical Capacitance/Conductance-Voltage Characteristics of Stored Charges in Organic Light-Emitting Diodes
Next Article in Special Issue
N-Heterocyclic Carbene Platinum(IV) as Metallodrug Candidates: Synthesis and 195Pt NMR Chemical Shift Trend
Previous Article in Journal
Cytotoxicity Evaluation of Novel bis(2-aminoethyl)amine Derivatives
Previous Article in Special Issue
Selenonium Ylides: Syntheses, Structural Aspects, and Synthetic Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 12
10.3390/molecules25122817
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites

by
Manel Ouji
1,2,†,
Guillaume Barnoin
1,†,
Álvaro Fernández Álvarez
1,
Jean-Michel Augereau
1,2,
Catherine Hemmert
1,*,
Françoise Benoit-Vical
1,2,3,* and
Heinz Gornitzka
1,*
1
CNRS, Laboratoire de Chimie de Coordination (LCC), Université de Toulouse, UPS, INPT, 205 route de Narbonne, BP 44099, F-31077 Toulouse CEDEX 4, France
2
Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, 31077 Toulouse, France
3
INSERM, Institut National de la Santé et de la Recherche Médicale, 31024 Toulouse, France
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2020, 25(12), 2817; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules25122817
Submission received: 20 May 2020 / Revised: 12 June 2020 / Accepted: 17 June 2020 / Published: 18 June 2020
(This article belongs to the Special Issue Carbon Ligands: From Fundamental Aspects to Applications)
Browse Figure
Versions Notes

Abstract

:
The emergence of Plasmodium falciparum parasites, responsible for malaria disease, resistant to antiplasmodial drugs including the artemisinins, represents a major threat to public health. Therefore, the development of new antimalarial drugs or combinations is urgently required. In this context, several hybrid molecules combining a dihydroartemisinin derivative and gold(I) N-heterocyclic carbene (NHC) complexes have been synthesized based on the different modes of action of the two compounds. The antiplasmodial activity of these molecules was assessed in vitro as well as their cytotoxicity against mammalian cells. All the hybrid molecules tested showed efficacy against P. falciparum, in a nanomolar range for the most active, associated with a low cytotoxicity. However, cross-resistance between artemisinin and these hybrid molecules was evidenced. These results underline a fear about the risk of cross-resistance between artemisinins and new antimalarial drugs based on an endoperoxide part. This study thus raises concerns about the use of such molecules in future therapeutic malaria policies.

1. Introduction

Plasmodium falciparum, the protozoan parasite causing malaria, was responsible for 228 million cases with 405,000 deaths in 2018, mainly in Sub-Saharan Africa where about 90% of the deaths affect children under five [1]. The current malaria treatments recommended by the WHO are artemisinin-based combination therapies (ACTs) combining an artemisinin derivative with one or two other antimalarial drugs with the particularity of having different modes of action and different pharmacokinetic properties. The use of these drug combinations has contributed to a significant decrease in malaria mortality in all endemic regions these last 20 years. However, since 2008, resistance of P. falciparum to artemisinins and partner drugs has widely spread in South-East Asia, resulting in a loss of efficacy of many antimalarial drugs to treat patients [2,3,4]. This situation is a major threat to global public health [5] and imposes a need to accelerate the discovery of new compounds able to eliminate resistant parasites. Among the strategies followed to improve the efficacy of artemisinin both directly against the parasite or for pharmacokinetic and pharmacodynamic enhancements, the synthesis of artemisinin dimers is proposed [6,7,8]. One of the aims was to amplify oxidative stress through increased production of reactive oxygen species (ROS) to kill the parasites. However, although some of these compounds show antiplasmodial activities in the nanomolar range, they have not been evaluated in an artemisinin resistance framework needing particular assays. Indeed, because artemisinin resistance is based on a quiescence mechanism corresponding to a cell cycle arrest of a small number of parasites during artemisinins treatment and resumption of their growth when the drug is eliminated [9,10,11], specific compounds have to be designed. Artemisinin resistance is also associated with mutations in the propeller domain of the gene pfk13 linked to a complex combination of different biochemical pathways [10,12,13]. It is to note that, at the quiescent state, the parasite’s metabolism is greatly downregulated. However, apicoplast and mitochondrion seem still active in quiescent parasites [14]. Targeting these two organelles appears thus as a very promising avenue to kill quiescent artemisinin-resistant parasites. In this context, we have recently synthetized and evaluated hybrid gold(I) N-heterocyclic carbene (NHC) complexes based on triclosan targeting mitochondrion and apicoplast, respectively [12]. These novel hybrids showed a strong antiplasmodial activity, however a cross-resistance trend with artemisinins was noted [12]. Interestingly, we showed that there is no cross-resistance between a gold(I) complex and artemisinins [12]. This is in accordance with former studies showing that atovaquone, a mitochondrial electron transfer inhibitor, was efficient not only on proliferating parasites but also on artemisinin-pretreated and dormant parasites [15,16].
Here, we focused our investigations on the second organelle involved in the quiescence mechanism: the parasite mitochondrion. In addition to its role as an energy supplier, mitochondrion contains a wide variety of additional processes notably the two major antioxidant defence systems: thioredoxin (Trx) and glutathione systems, Trx being essential for the erythrocytic P. falciparum cycle [17].
Our chemical research is mainly focused on the design of bioactive gold(I) NHC complexes for parasitic diseases, P. falciparum [18,19,20] and Leishmania infantum [21,22], and anticancer applications [23,24,25]. Moreover, in the field of anticancer metal-based agents, the ubiquitous selenoenzyme thioredoxin reductase (TrxR), responsible for cell homeostasis regulation, is considered as one of the most relevant targets for gold(I) complexes and inhibition of TrxR could lead to apoptosis though a mitochondrial pathway [24,25,26]. Considering that artemisinins—and dihydroartemisinin, the active metabolite of all artemisinin derivatives—are active against all erythrocytic stages of P. falciparum and are still the best antiplasmodial drugs on the field, we designed hybrid complexes combining an ether derivative of dihydroartemisinin (called here DHA) with a gold(I) cation, covalently integrated in our NHC ligand systems. This approach aims to firstly eliminate most of the parasite stages thanks to the highly active DHA part, thereafter, the remaining resistant quiescent parasites will be treated by the gold(I) moiety. The goal of this work is to determine the activity of these hybrid molecules against P. falciparum, then to evaluate the efficacy of the most active hybrids in a context of artemisinin resistance.

2. Results and Discussion

2.1. Chemistry

The gold(I) complexes designed here are divided in three series depending on the length of the spacers between the carbene and the pharmacophore derivative. In order to fuse DHA and NHCs precursors we used aliphatic linkers containing 3 to 5 carbon atoms. The synthetic pathway involves three steps (Scheme 1). First, etherification of DHA with a bromoalcohol in the presence of boron trifluoride etherate catalyst [27,28] gave after purification the single β-isomers DHA-C3 to DHA-C5. The next step was the quaternization of a substituted imidazole, either commercially available (Me, iPr and Bn) or previously described in the literature (Mes, Quin) [22,29], to obtain the corresponding carbene precursors Ln-R(1–13) in yields ranging from 35 to 98%. They were classically characterized by 1H- and 13C-NMR spectroscopy, mass spectrometry and elemental analysis. The most notable features in the 1H- and 13C-NMR spectra of the imidazolium salts are the resonances for the imidazolium protons (H2) located between 10.07 and 12.15 ppm, the upfield value being attributed to the proligands containing a quinoline group and the corresponding imidazolium carbons (C2) in the range of 135.7–138.7 ppm. The formation of the target gold(I) complexes was achieved by direct metalation involving K2CO3 as base and Au(SMe2)Cl, in a ratio 2:1 for the cationic Aubis(n-R) complexes 15–26 and in a ratio 1:1 for the neutral Au(n-R)Cl ones (27 and 28). Complexes Aubis(L3-Me) (14), was synthetized by the convenient transmetalation route involving the mild base Ag2O, followed by an ion exchange with AgNO3 and subsequent addition of Au(SMe2)Cl [28]. The neutral complex Au(3-Quin)Cl (29) was obtained as a byproduct from the purification by column chromatography of Aubis(3-Quin) (18). The gold(I) complexes 15–26 were isolated after purification as white solids with yields of 31 to 92%. All compounds were characterized by 1H- and 13C-NMR spectroscopy, high-resolution mass spectrometry and elemental analysis. 13C-NMR spectroscopy unequivocally evidences the formation of the cationic gold(I) complexes Aubis(n-R) (15–26) with resonance of the carbenic carbons located at 181.8-183.9 ppm. In the case of mono-NHC complexes Au(n-R)Cl (27–29), the most characteristic features in 13C NMR spectra are the C2 peaks at 173.3, 174.5 and 173.7 ppm for Au(3-iPr)Cl (27), Au(3-Bn)Cl (28) and Au(3-Quin)Cl (29), respectively. The elemental analysis for the gold(I) complexes correspond to the general formula [AuL2][Cl] (except for Aubis(L3-Me) (14) with nitrate anion) for the bis(NHC) complexes Aubis(n-R) (15–26) and AuLCl for the mono(NHC) complexes Au(n-R)Cl (27–29). The high resolution mass spectra (ESI+) HRMS spectra of all gold(I) complexes exhibit the classical peak m/z for the cationic fragment [M–X−]+.

2.2. Antiplasmodial Activity and Selectivity

The proligands (Ln-R) and the complexes (Aubis(n-R) and Au(n-R)Cl) as well as reference molecules, artemisinin, artemether, auranofin and the proligand precursor DHA-C3, were screened in vitro against the P. falciparum strain F32-Tanzania and the cytotoxicity on Vero cells was evaluated to determine the selectivity of the most active compounds (Table 1). Globally, the results are extremely interesting, with IC50 values against Plasmodium ranging from 9 to 935 nM for the proligands and the gold(I) complexes. The DHA-ether derivative used for the synthesis of the proligands containing a C3 lateral chain, DHA-C3, has an IC50 value of 8.5 nM comparable to that of the antimalarial reference drug artemether (IC50 = 6.1 nM). Surprisingly, for the imidazolium salts obtained by addition of a substituted imidazole moiety to DHAC3-C5 precursors, a significant loss of the antimalarial activity was observed (IC50 = 98–935 nM, entries 5–9, 18-21 and 26–29). In contrast, the presence of the gold(I) cation in the corresponding complexes greatly improved the antiplasmodial efficacy (IC50 = 9–104 nM, entries 10–17, 22–25 and 30–33) compared to the corresponding proligands. The antiplasmodial activity was notable, with IC50 values below 100 nM for two proligands in the C5 series (L5-Bn (11) and L5-Mes (12) and for the majority of the cationic and neutral gold(I) complexes. By comparison, auranofin, a gold-based reference molecule used for the treatment of rheumatoid arthritis, was not active against P. falciparum parasites with a higher IC50 value of 1.5 µM.
Moreover, ten complexes are highly efficient, with IC50 values lower than 50 nM, including nine cationic gold(I) bis(NHC) complexes and one neutral NHC-Art complex, namely Au(3-iPr)Cl) (27). Among them, five complexes, namely Aubis(3-iPr) (15), Aubis(3-Bn) (16), Aubis(3-Quin) (18), Aubis(4-Me) (19) and Aubis(5-Me) (23) have an antiplasmodial activity comparable (an IC50 between 9 and 23 nM) to the reference antimalarial drugs artemisinin (IC50 = 18 nM) and artemether (IC50 = 6.1 nM). Regarding structure activity relationship, the potency of the complexes containing methyl (14, 19 and 23) or benzyl (16, 20 and 24) groups on the NHCs increased with the length of the spacer whereas, no correlation was highlighted for the mesityl and the quinoline series (17, 21, 25, and 18, 22, 26, respectively). Surprisingly while artemether and DHA-C3 had the same antiplasmodial activity, the selectivity indexes (SI) were largely higher for artemether (SI = 35,000) than for DHA-C3 (SI = 294) demonstrating that the C3 moiety seems less selective. The selectivity indexes for the tested proligands and gold(I) complexes were between 8 and 255, the best value being obtained for the proligand L5-Mes (12, IC50 = 98 nM). Interestingly, regardless of the number of carbons in the spacer, hybrid molecules with aliphatic R groups (Me, iPr) have the best selectivities with SI values of 143 and 178 for Aubis(3-Me) (14) and Au(3-iPr)Cl (27), respectively, 62 for Aubis(4-Me) (19) and 111 for Aubis(5-Me) (23), in comparison with aromatic groups.

2.3. In Vitro Cross-Resistance between Hybrid Molecules and Artemisinin

Three hybrid molecules with the best selectivity indexes in each series, i.e., Aubis(3-Me) (14), Aubis(4-Me) (19) and Aubis(5-Me) (23), were evaluated in vitro for their efficacy in a context of resistance to artemisinins. For that, the comparison of the recovery capacity between the strain F32-ART, artemisinin-resistant, and its twin artemisinin-sensitive F32-TEM was evaluated after 48 h-treatment with the molecule to be tested via the recrudescence assay [9,15]. When ring-stage resistant parasites are exposed to artemisinin, most of them die, but a small sub-set of parasites is able to escape the treatment by a cell cycle arrest, called quiescence mechanism. This phenomenon is characterized by a halt of DNA synthesis, which explains the very low IC50 values obtained with all artemisinins even for the artemisinin-resistant strain F32-ART [9,15,30]. Therefore, the standard in vitro chemosensitivity assay, based on the measurement of DNA levels to estimate the inhibition of the parasite proliferation, is irrelevant to study the resistance to artemisinins and evaluate possible cross-resistances.
The validation of the test was here done thanks to the results obtained after 18 µM artemisinin treatment and demonstrating that F32-ART is able to recrudesce faster than F32-TEM with a difference to reach the initial parasitemia between the two strains of 9.7 days (Table 2). For the three hybrid molecules tested, namely Aubis(3-Me) (14), Aubis(4-Me) (19) and Aubis(5-Me) (23), Table 2 showed a difference of recrudescence between F32-ART and F32-TEM. Whatever the hybrid tested, the differences of recrudescence between both strains rise at the higher doses confirming that increase the doses of the molecules to be tested allows a better discrimination of the recrudescence capacity between the artemisinin-resistant and the -sensitive strains [9]. According to the obtained results, a cross-resistance between artemisinin and the hybrid molecules Aubis(3-Me) (14), Aubis(4-Me) (19) and Aubis(5-Me) (23) was noted. This cross-resistance could be explained by the DHA part of the hybrid, responsible for the quiescence entrance of the parasites and the lack of activity of the NHC part at the mitochondrial level due to limited access or pharmacodynamic properties. These data are in accordance with previously obtained results which highlighted the risks of parasites cross-resistance between artemisinins and endoperoxide-based compounds [31,32].

3. Materials and Methods

3.1. Chemistry

3.1.1. General Information

All complexation reactions were performed under an inert atmosphere of dry nitrogen by using standard vacuum line and Schlenk tube techniques. Reactions involving silver compounds were performed with the exclusion of light. CH3CN was dried over CaH2 and subsequently distilled. 10β-(20-Bromopropoxy)dihydroartemisinin (DHA-C3) [27], 10β-(21-bromobutoxy)dihydroartemisinin (DHA-C4), 10β-(22-bromopentoxy)dihydroartemisinin (DHA-C5), 3′-methyl-1′-[10β-(20-propoxy)-dihydroartemisinin]1H-imidazol-3-ium bromide (L3-Me (1)), 3′-methyl-1′-[10β-(21-butoxy)-dihydroartemisinin]1H-imidazol-3-ium bromide (L4-Me (2)), 3′-methyl-1′-[10β-(22-pentoxy)-dihydroartemisinin]1H-imidazol-3-ium bromide (L5-Me (3)), complexes Aubis(3-Me) (14), Aubis(4-Me) (19), Aubis(5-Me) (23) [28], 1-mesitylimidazole [29] and 2-(2H-imidazol-1-yl)quinoline [22] were synthetized according to the referenced literature procedures. All other reagents were used as received from commercial suppliers. 1H- (300, 400 or 500 MHz) and 13C-NMR spectra (75, 101 or 126 MHz) were recorded at 298 K on AV300, AV400 or Avance 500 spectrometers (Bruker, Billerica, MA) in CDCl3 as solvent. All chemical shifts for 1H and 13C are relative to TMS using 1H (residual) or 13C chemical shifts of the solvent as a secondary standard. High Resolution Mass Spectrometry (HRMS) analysis were performed with a Xévo G2 QTOF spectrometer (Waters Corporation, Milford, MA) using electrospray ionization (ESI) by the “Service de Spectrométrie de Masse de Chimie UPS-CNRS (University of Toulouse, France)”. Elemental analyses were carried out by the “Service de Microanalyse du Laboratoire de Chimie de Coordination (Toulouse, France)”.

3.1.2. Synthesis of proligands (Ln-R) and gold(I) complexes Aubis(n-R) and Au(n-R)Cl

3′-Isopropyl-1′-[10β-(20-propoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L3-iPr, (1)). To a stirred solution of DHA-C3 (164 mg, 0.4 mmol) in CH3CN (10 mL), 1-isopropylimidazole (61.7 mg, 0.4 mmol) was added and the reaction mixture was stirred 1 day at 70 °C. Then, the solvent was evaporated under reduced pressure and the viscous residue was washed with diethylether to afford a yellow powder (97 mg, 47% yield). Anal. Calcd. for C24H39BrN2O5: C, 55.92; H, 7.63; N, 5.43. Found C, 55.85; H, 7.64; N, 5.89. 1H-NMR (300 MHz, CDCl3): δ 10.67 (s, 1H, H2), 7.48 (d, J = 1.8 Hz, 1H, H4), 7.40 (d, J = 1.8 Hz, 1H, H5), 5.38 (s, 1H, HArt), 4.93 (h, J = 6.6, 5.6 Hz, 1H, HiPr), 4.78 (d, J = 3.2 Hz, 1H, HArt), 4.52–4.46 (m, 2H, HCH2), 3.92–3.84 (m, 1H, HCH2), 3.54–3.46 (m, 1H, HCH2), 2.71–2.57 (m, 1H, HArt), 2.40–2.22 (m, 3H, HArt, HCH2), 2.07–1.97 (s, 2H, HArt), 1.96–1.84 (m, 1H, HArt), 1.81–1.69 (m, 2H, HArt), 1.65 (s, 3H, HiPr), 1.63 (s, 3H, HiPr), 1.54–1.45 (m, 2H, HArt), 1.41 (s, 3H, HArt), 1.38–1.32 (m, 1H, HArt), 1.29–1.20 (m, 1H, HArt), 0.96 (d, J = 6.1 Hz, 3H, HArt), 0.95–0.86 (m, 1H, HArt), 0.92 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 136.5 (1C, C2), 122.3 (1C, C4), 119.9 (1C, C5), 104.2 (1C, CArt), 102.2 (1C, CArt), 88.0 (1C, CArt), 80.9 (1C, CArt), 64.7 (1C, CCH2), 53.5 (1C, CiPr), 52.4 (1C, CArt), 47.4 (1C, CCH2), 44.2 (1C, CArt), 37.5 (1C, CArt), 36.3 (1C, CArt), 34.5 (1C, CArt), 30.8 (1C, CCH2), 30.7 (1C, CArt), 26.1 (1C, CArt), 24.6 (1C, CArt), 24.6 (1C, CArt), 23.2 (2C, CiPr), 20.3 (1C, CArt), 13.2 (1C, CArt). HRMS (ESI+): calcd. for C24H39N2O5 m/z = 435.2859, found 435.2856.
3′-Benzyl-1′-[10β-(20-propoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L3-Bn, (2)). To a stirred solution of DHA-C3 (275 mg, 0.68 mmol) in CH3CN (4 mL) heated at 70 °C, 1-benzylimidazole (107 mg, 0.68 mmol) was added and the reaction mixture was stirred 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a sticky white solid (286 mg, 87% yield). Anal. Calcd. for C28H39BrN2O5: C, 59.68; H, 6.98; N, 4.97. Found C, 59.57; H, 6.95; N, 4.90. 1H-NMR (400 MHz, CDCl3): δ 10.71 (s, 1H, H2), 7.52 (m, 1H, HBn), 7.51 (d, J = 1.8 Hz, 1H, H4), 7.40 (d, J = 1.8 Hz, 1H, H5), 7.39 (m, 2H, HBn), 7.34 (d, J = 1.6 Hz, 2H, HBn), 5.64 (s, 2H, HBn), 5.37 (s, 1H, HArt), 4.76 (d, J = 3.6 Hz, 1H, HArt), 4.40-4.44 (m, 2H, HCH2), 3.90–3.85 (m, 1H, HCH2), 3.51–3.44 (m, 1H, HCH2), 2.62–2.66 (m, 1H, HArt), 2.40–2.32 (m, 1H, HArt), 2.29–2.23 (m, 2H, HCH2), 2.05 (m, 1H, HArt), 2.01 (m, 1H, HArt),1.92–1.86 (m, 1H, HArt), 1.78–1.74 (m, 1H, HArt), 1.69–1.63 (m, 2H, HArt), 1.50–1.43 (m, 2H, HArt), 1.41 (s, 3H, HArt), 1.33–1.37 (m, 1H, HArt), 1.28–1.24 (m, 1H, HArt), 0.96 (d, J = 6.3 Hz, 3H, HArt), 0.92 (m, 1H, HArt), 0.89 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 137.7 (1C, C2), 132.7 (1C, CBn), 129.7 (2C, CBn), 129.5 (1C, CBn), 129.1 (2C, CBn), 122.1 (1C, C4), 121.5 (1C, C5), 104.3 (1C, CArt), 102.3 (1C, CArt), 88.0 (1C, CArt), 80.9 (1C, CArt), 64.6 (1C, CCH2), 53.6 (1C, CBn), 52.4 (1C, CArt), 47.6 (1C, CCH2), 44.2 (1C, CArt), 37.5 (1C, CArt), 36.3 (1C, CArt), 34.4 (1C, CArt), 30.8 (1C, CCH2), 30.5 (1C, CArt), 26.1 (1C, CArt), 24.7 (1C, CArt), 24.6 (1C, CArt), 20.3 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C28H39N2O5 m/z = 483.2855, found 483.2859.
3′-Mesityl-1′-[10β-(20-propoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L3-Mes, (3)). To a stirred solution of DHA-C3 (251 mg, 0.62 mmol) in CH3CN (4 mL) heated at 70 °C, 1-mesitylimidazole (115 mg, 0.62 mmol) was added and the reaction mixture was stirred for 3 days. The solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (238 mg, 76% yield). Anal. Calcd. for C30H43BrN2O5: C, 60.91; H, 7.33; N, 4.74. Found C, 60.93; H, 7.27; N, 4.65. 1H-NMR (300 MHz, CDCl3): δ 10.49 (s, 1H, H2), 7.76 (t, J = 1.8 Hz, 1H, H4), 7.17 (t, J = 1.8 Hz, 1H, H4), 7.03 (m, 2H, HMes), 5.45 (s, 1H, HArt), 4.92 (m, 1H, HArt), 4.87–4.76 (m, 2H, HCH2), 3.90–3.83 (m, 1H, HCH2), 3.65–3.54 (m, 1H, HCH2), 2.71–2.66 (m, 1H, HArt), 2.36 (s, 3H, HMes), 2.44–2.33 (m, 3H, HArt), 2.11 (s, 6H, HMes), 2.06–2.00 (m, 1H, HArt), 1.95–1.84 (m, 1H, HArt), 1.83–1.78 (m, 1H, HArt), 1.77–1.67 (m, 2H, HArt), 1.65 (s, 1H, HArt), 1.54–1.48 (m, 2H, HArt), 1.45–1.36 (m, 1H, HArt), 1.37 (s, 3H, HArt), 1.32–1.26 (m, 1H, HArt), 0.98 (d, J = 6.2 Hz, 3H, HArt), 0.94 (m, 1H, HArt), 0.93 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 141.2 (1C, CMes), 137.7 (1C, C2), 134.2 (2C, CMes), 130.7 (1C, CMes), 129.8 (2C, CMes), 123.6 (1C, C4), 123.6 (1C, C5), 104.2 (1C, CArt), 102.2 (1C, CArt), 87.9 (1C, CArt), 81.0 (1C, CArt), 64.7 (1C, CCH2), 52.4 (1C, CArt), 47.6 (1C, CCH2), 44.2 (1C, CArt), 37.4 (1C, CArt), 36.3 (1C, CArt), 36.1 (1C, CArt), 34.4 (1C, CCH2), 30.9 (1C, CArt), 30.1 (1C, CArt), 25.9 (1C, CArt), 24.6 (1C, CArt), 24.5 (1C, CArt), 21.1 (1C, CMes), 20.3 (1C, CArt), 17.6 (1C, CMes), 13.2 (1C, CArt). HRMS (ESI+): calcd. for C30H43N2O5 m/z = 511.3174, found 511.3172.
3′-Quinolin-2-yl-1′-[10β-(20-propoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L3-Quin, (4)). To a stirred solution of DHA-C3 (292 mg, 0.72 mmol) in CH3CN (3 mL) heated at 70)° C, 1-(quinolin-2-yl)-imidazole (140 mg, 0.72 mmol) was added and the reaction mixture was stirred for 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a yellow solid (315 mg, 84 % yield). Anal. Calcd. for C30H38BrN3O5: C, 60.00; H, 6.38; N, 7.00. Found C, 60.15; H, 6.42; N, 6.95. 1H-NMR (400 MHz, CDCl3): δ 12.15 (s, 1H, H2), 8.71 (m, 1H, HQuin), 8.56–8.53 (m, 2H, H4, HQuin), 8.06 (d, J = 8.5 Hz, 1H, HQuin), 7.96 (d, J = 7.8 Hz, 1H, HQuin), 7.84 (m, 1H, HQuin), 7.68 (m, 1H, HQuin), 7.54 (t, J = 1.7 Hz, 1H, H5), 5.43 (s, 1H, HArt), 4.83 (d, J = 3.6 Hz, 1H, HArt), 4.75 (m, 2H, HCH2), 4.78–4.70 (m, 2H, HCH2), 4.02–3.96 (m, 1H, HCH2), 3.65–3.60 (m, 1H, HCH2), 2.68 (m, 1H, HArt), 2.47–2.41 (m, 2H, HCH2), 2.39–2.35 (m, 1H, HArt), 2.08–2.02 (m, 1H, HArt), 1.94–1.84 (m, 1H, HArt), 1.82–1.77 (m, 1H, HArt), 1.72–1.65 (m, 2H, HArt), 1.56–1.45 (m, 2H, HArt), 1.44 (s, 3H, HArt), 1.40–1.34 (m, 1H, HArt), 1.30–1.23 (m, 1H, HArt), 0.97 (d, J = 6.4 Hz, 3H, HArt), 0.95 (d, J = 7.4 Hz, 3H, HArt), 0.91–0.85 (m, 1H, HArt). 13C NMR (101 MHz, CDCl3): δ 146.1 (1C, CQuin), 144.5 (1C, CQuin), 141.7 (1C, CQuin), 137.0 (1C, C2), 131.5 (1C, CQuin), 128.8 (1C, CQuin), 128.3 (1C, CQuin), 128.2 (2C, CQuin), 122.4 (1C, C4), 118.7 (1C, C5), 112.7 (1C, CQuin), 104.3 (1C, CArt), 102.3 (1C, CArt), 88.0 (1C, CArt), 80.9 (1C, CArt), 64.8 (1C, CCH2), 52.4 (1C, CArt), 49.2 (1C, CCH2), 44.2 (1C, CArt), 37.5 (1C, CArt), 36.3 (1C, CArt), 34.5 (1C, CArt), 30.8 (1C, CCH2), 30.8 (1C, CArt), 26.1 (1C, CArt), 24.6 (1C, CArt), 24.6 (1C, CArt), 20.3 (1C, CArt), 13.2 (1C, CArt). HRMS (ESI+): calcd. for C30H38N3O5 m/z = 520.2798, found 520.2811.
ComplexAubis(3-iPr) (15). Under a nitrogen atmosphere and protection of the light, L3-iPr (102 mg, 0.2 mmol) and Ag2O (26 mg, 0.11 mmol) was dissolved in CH3CN (3 mL) and stirred overnight at rt. Then, AgNO3 (19 mg, 0.11 mmol) was added to the mixture followed 2 h later by addition of Au(SMe2)Cl (32 mg, 0.11 mmol). After stirring 1 h at rt, the solution was filtered through a pad of celite and the solvent removed under reduced pressure to afford a white solid after centrifugation (95 mg, 83% yield). Anal. Calcd. For C48H76AuClN4O10: C, 52.34; H, 6.95; N, 5.09. Found C, 52.28; H, 6.85; N, 5.02. 1H-NMR (400 MHz, CDCl3): δ 7.31 (d, J = 1.9 Hz, 1H, H4), 7.30 (s, 1H, H5), 5.39 (s, 1H, HArt), 4.95 (h, J = 6.9 Hz, 1H, HiPr), 4.80 (d, J = 3.6 Hz, 1H, HArt), 4.42–4.31 (m, 2H, HCH2), 3.95–3.89 (m, 1H, HCH2), 3.49–3.43 (m, 1H, HCH2), 2.68–2.64 (m, 1H, HArt), 2.39 (td, J = 14.0, 3.9 Hz, 1H, HArt), 2.31–2.18 (m, 2H, HCH2), 2.08–2.03 (m, 1H, HArt), 1.94–1.89 (m, 1H, HArt), 1.78–1.65 (m, 3H, HArt), 1.62 (s, 3H, HiPr), 1.60 (s, 3H, HiPr), 1.52–1.47 (m, 2H, HArt), 1.44 (s, 3H, HArt), 1.36–1.25 (m, 2H, HArt), 0.98 (d, J = 6.1 Hz, 3H, HArt), 0.97–0.88 (m, 1H, HArt), 0.93 (d, J = 7.3 Hz, 3H, Art). 13C NMR (101 MHz, CDCl3): δ 182.1 (1C, C2), 122.3 (1C, C4), 118.3 (1C, C5), 104.2 (1C, CArt), 102.0 (1C, CArt), 88.0 (1C, CArt), 80.9 (1C, CArt), 64.8 (1C, CCH2), 53.8 (1C, CiPr), 52.4 (1C, CArt), 48.9 (1C, CCH2), 44.2 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 31.7 (1C, CCH2), 30.8 (1C, CArt), 26.1 (1C, CArt), 24.7 (1C, CArt), 24.6 (1C, CArt), 23.8 (1C, CiPr), 23.8 (1C, CiPr), 20.3 (1C, CArt), 13.2 (1C, CArt). HRMS (ESI+): calcd. for C48H76AuClN4O10 m/z = 1065.5227, found 1065.5220.
ComplexAubis(3-Bn) (16). Under a nitrogen atmosphere, K2CO3 (26 mg, 0.19 mmol) was added to L3-Bn (108 mg, 0.19 mmol) in dry CH3CN (4 mL) and heated at 60 °C under stirring. Then, Au(SMe2)Cl (28 mg, 0.096 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a white solid (75 mg, 65 % yield). Anal. Calcd. for C56H76AuClN4O10: C, 56.16; H, 6.40; N, 4.48. Found C, 56.28; H, 6.55; N, 4.42. 1H-NMR (500 MHz, CDCl3): δ 7.34 (d, J = 1.9 Hz, 1H, H4), 7.30 (m, 2H, HBn), 7.29 (m, 1H, HBn), 7.24 (m, 2H, HBn), 7.23 (d, J = 1.9 Hz, 1H, H5), 5.39 (s, 2H, HBn), 4.74 (d, J = 3.5 Hz, 1H, HArt), 4.28–4.24 (m, 2H, HCH2), 3.87–3.81 (m, 1H, HCH2), 3.41–3.36 (m, 1H, HCH2), 2.64–2.60 (m, 1H, HArt), 2.41–2.33 (m, 1H, HArt), 2.11 (m, 2H, HCH2), 2.07–2.01 (m, 1H, HArt), 1.91–1.85 (m, 2H, HArt), 1.74–1.69 (m, 2H, HArt), 1.63–1.57 (m, 1H, HArt), 1.41–1.46 (m, 2H, HArt), 1.41 (s, 3H, HArt), 1.33–1.26 (m, 2H, HArt), 0.94 (d, J = 6.1 Hz, 3H, HArt), 0.92 (m, 1H, HArt), 0.87 (d, J = 7.3 Hz, 3H, HArt). 13C NMR (126 MHz, CDCl3): δ 183.5 (1C, C2), 135.7 (1C, CBn), 129.1 (2C, CBn), 128.6 (1C, CBn), 127.6 (2C, CBn), 122.5 (1C, C4), 122.2 (1C, C5), 104.2 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 80.9 (1C, CArt), 64.7 (1C, CCH2), 54.8 (1C, CBn), 52.5 (1C, CArt), 48.6 (1C, CCH2), 44.2 (1C, CArt), 37.6 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 31.6 (1C, CCH2), 30.7 (1C, CArt), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 20.3 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C56H76AuN4O10 m/z = 1161.5227, found 1161.5247.
ComplexAubis(3-Mes) (17). Under a nitrogen atmosphere, K2CO3 (24 mg, 0.17 mmol) was added to L3-Mes (104 mg, 0.17 mmol) in dry CH3CN (4 mL). The mixture was then heated at 60 °C. After, Au(SMe2)Cl (26 mg, 0.087 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a yellow solid (58 mg, 52% yield). Anal. Calcd. for C60H84AuClN4O10: C, 57.48; H, 6.75; N, 4.47. Found C, 57.42; H, 6.68; N, 4.35. 1H-NMR (500 MHz, CDCl3): δ 7.59 (d, J = 1.9 Hz,1H, H4), 6.96 (m, 3H, H5, HMes), 5.37 (s, 1H, HArt), 4.73 (d, J = 3.5 Hz, 1H, H1Art), 4.13 (m, 2H, HCH2), 3.72 (m, 1H, HCH2), 3.22 (m, 1H, HCH2), 2.65 (m, 1H, HArt), 2.37 (s, 3H, HMes), 2.41–2.33 (m, 1H, HArt), 2.09–1.98 (m, 2H, HCH2), 1.90 (m, 1H, HArt), 1.85 (s, 3H, HMes), 1.83 (m, 3H, HMes), 1.83–1.65 (m, 4H, HArt), 1.51–1.45 (m, 2H, HArt), 1.43 (m, 1H, HArt), 1.36–1.32 (m, 1H, HArt), 1.29–1.25 (s, 1H, HArt), 0.98 (d, J = 6.3 Hz, 3H, HArt), 0.96–0.88 (m, 1H, HArt), 0.94 (d, J = 7.2 Hz, 3H, HArt). 13C NMR (126 MHz, CDCl3): δ 183.8 (1C, C2), 139.6 (1C, CMes), 134.8 (2C, CMes), 134.7 (1C, CMes), 129.2 (2C, CMes), 123.0 (1C, C5), 122.7 (1C, C4), 104.1 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 81.0 (1C, CArt), 64.8 (1C, CCH2), 52.5 (1C, CArt), 48.3 (1C, CCH2), 44.2 (1C, CArt), 37.7 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 31.6 (CCH2), 30.9 (1C, CArt), 26.1 (1C, CArt), 24.7 (1C, CArt), 24.6 (1C, CArt), 21.2 (2C, CMes), 20.3 (1C, CArt), 17.6 (1C, CMes), 13.3 (1C, CArt). HRMS (ESI+): calcd. for C60H74AuN6O10 m/z = 1235.5157, found 1235.5132.
ComplexAubis(3-Quin) (18). Under a nitrogen atmosphere, K2CO3 (24 mg, 0.17 mmol) was added to L3-Quin (100 mg, 0.17 mmol) in dry CH3CN (4 mL). The stirred mixture was then heated at 60 °C. Then, Au(SMe2)Cl (25 mg, 0.085 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure to give a white solid (93 mg, 86% yield). Anal. Calcd. For C60H74AuClN6O10: C, 56.67; H, 5.87; N, 6.61. Found C, 56.62; H, 5.85; N, 6.54. 1H-NMR (500 MHz, CDCl3): δ 8.30 (d, J = 8.6 Hz, 1H, HQuin), 8.13 (d, J = 8.7 Hz, 1H, HQuin), 8.09 (d, J = 1.6 Hz, 1H, H4), 7.80 (d, J = 8.4 Hz, 1H, HQuin), 7.73 (d, J = 8.2 Hz, 1H, HQuin), 7.62 (m, 1H, HQuin), 7.51 (d, J = 2.0 Hz, 1H, H5), 7.47 (m, 1H, HQuin), 5.34 (s, 1H, HArt), 4.71 (d, J = 3.5 Hz, 1H, HArt), 4.53–4.44 (m, 2H, HCH2), 3.87–3.82 (m, 1H, HCH2), 3.43–3.38 (m, 1H, HArt), 2.61–2.56 (m, 1H, HArt), 2.33 (td, J = 14.0, 4.0 Hz, 1H, HArt), 2.26–2.18 (m, 2H, HCH2), 2.02–1.97 (m, 1H, HArt), 1.86–1.81 (m, 1H, HArt), 1.67–1.62 (m, 2H, HArt), 1.54–1.50 (m, 1H, HArt), 1.46–1.35 (m, 2H, HArt), 1.39 (m, 3H, HArt), 1.30-1.16 (m, 2H, HArt), 0.88 (d, J = 6.2 Hz, 3H, HArt), 0.86–080 (m, 1H, HArt), 0.83 (d, J = 7.2 Hz, 3H, HArt). 13C NMR (126 MHz, CDCl3): δ 181.8 (1C, C2), 148.9 (1C, CQuin), 146.3 (1C, CQuin), 139.9 (1C, CQuin), 131.0 (1C, CQuin), 128.4 (1C, CQuin), 127.9 (1C, CQuin), 127.6 (1C, CQuin), 127.5 (1C, CQuin), 122.9 (1C, C4), 121.6 (1C, C5), 115.7 (1C, CQuin), 104.2 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 80.9 (1C, CArt), 64.8 (1C, CCH2), 52.4 (C1, CArt), 49.8 (1C, CCH2), 44.2 (1C, CArt), 37.6 (1C, CArt), 36.3 (1C, CArt), 34.5 (1C, CArt), 31.5 (1C, CCH2), 30.7 (1C, CArt), 26.1 (1C, CArt), 24.6 (1C, CArt), 24.5 (1C, CArt), 20.3 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C60H74AuN6O10 m/z = 1235.5157, found 1235.5132.
ComplexAu(3-iPr)Cl (27). Under a nitrogen atmosphere and protection of the light, L3-iPr (21 mg, 0.04 mmol), K2CO3 (6 mg, 0.04 mmol) and Au(SMe2)Cl (12 mg, 0.04 mmol) were dissolved in CH3CN (3 mL) and stirred for 6 h at 60 °C. The solution was filtered through a syringe filter (0.2 µm) and the solvent removed under reduced pressure to afford a white powder (9.8 mg, 42% yield). Anal. Calcd. for C24H38AuClN2O5: C, 43.22; H, 5.74; N, 4.20. Found C, 43.32; H, 5.72; N, 4.15. 1H-NMR (400 MHz, CDCl3): δ 7.01 (d, J = 2.0 Hz, 1H, H4), 6.97 (d, J = 1.9 Hz, 1H, H5), 5.41 (s, 1H, HArt), 5.10 (hept, J = 7.0 Hz, 1H, HiPr), 4.81 (d, J = 3.4 Hz, 1H, HArt), 4.26 (td, J = 7.1, 4.8 Hz, 2H, HCH2), 3.95–3.86 (m, 1H, HCH2), 3.48–3.40 (m, 1H, HCH2), 2.73–2.63 (m, 1H, HArt), 2.45–2.33 (m, 1H, HArt), 2.23–2.13 (m, 2H, HCH2), 2.06 (ddd, J = 14.0, 4.6, 2.9 Hz, 1H, HArt), 1.95–1.83 (m, 2H, HArt), 1.78–1.70 (m, 2H, HArt), 1.60–1.52 (s, 2H, HArt), 1.50 (s, 3H, HiPr), 1.48 (s, 3H, HiPr), 1.45 (s, 3H, HArt), 1.41–1.36 (m, 1H, HArt), 1.30–1.24 (m, 1H, HArt), 0.99 (d, J = 5.5 Hz, 3H, HArt), 0.98 (d, J = 5.5 Hz, 3H, HArt), 0.96–0.86 (m, 1H, HArt). 13C NMR (101 MHz, CDCl3): δ 173.3 (1C, C2), 120.9 (1C, C4), 116.4 (1C, C5), 104.2 (1C, CArt), 102.2 (1C, CArt), 88.0 (1C, CArt), 81.0 (1C, CArt), 64.8 (1C, CCH2), 53.6 (1C, CiPr), 52.5 (1C, CArt), 48.7 (1C, CCH2), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 31.3 (1C, CCH2), 30.9 (1C, CArt), 29.7 (1C, CArt), 26.2 (1C, CArt), 24.7 (2C, CArt), 23.4 (2C, CiPr), 20.3 (1C, CArt), 13.3 (1C, CArt). HRMS (ESI+): calcd. for C24H38AuN2O5 m/z = 631.2449, found 631.2446.
ComplexAu(3-Bn)Cl (28). Under a nitrogen atmosphere, K2CO3 (20 mg, 0.15 mmol) was added to L3-Bn (85 mg, 0.15 mmol) in dry CH3CN (7 mL). The mixture was then heated at 60 °C. After, Au(SMe2)Cl (44 mg, 0.15 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent was removed under reduced pressure to give a white solid (87 mg, 81% yield). Anal. Calcd. for C28H38AuClN2O5: C, 47.03; H, 5.36; N, 3.92. Found C, 47.12; H, 5.29; N, 3.91. 1H-NMR (400 MHz, CDCl3): δ 7.31–7.40 (m, 5H, HBn), 6.97 (d, J = 2.0 Hz, 1H, H4), 6.89 (d, J = 1.9 Hz, 1H, H5), 5.38 (s, 2H, HBn), 5.40 (s, 1H, HArt), 4.79 (d, J = 3.5 Hz, 1H, HArt), 4.31–4.24 (m, 2H, HCH2), 3.92–3.87 (m, 1H, HCH2), 3.46–4.40 (m, 1H, HCH2), 2.68–2.63 (m, 1H, HArt), 2.41–2.32 (ddd, J = 14.5, 13.4, 3.9 Hz, 1H, HArt), 2.24–2.21 (m, 2H, HCH2), 2.04 (ddd, J = 14.6, 4.8, 2.9 Hz, 1H, HArt), 1.93–1.68 (m, 4H, HArt), 1.55–1.44 (m, 2H, HArt), 1.43 (s, 3H, HArt), 1.39–1.33 (m, 1H, HArt), 1.29–1.22 (m, 1H, HArt), 0.97 (d, J = 6.1 Hz, 3H, HArt), 0.95 (d, J = 7.3 Hz, 3H, HArt), 0.94–0.88 (m, 1H, HArt). 13C NMR (101 MHz, CDCl3): δ 174.5 (1C, C2), 134.9 (1C, CBn), 129.1 (2C, CBn), 128.8 (2C, CBn), 128.1 (2C, CBn), 121.2 (1C, C4), 120.2 (1C, C5), 104.2 (1C, CArt), 102.2 (1C, CArt), 88.0 (1C, CArt), 81.0 (1C, CArt), 64.7 (1C, CCH2), 55.2 (1C, CBn), 52.5 (1C, CArt), 48.7 (1C, CCH2), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 31.2 (1C, CCH2), 30.9 (1C, CArt), 26.2 (1C, C1Art), 24.7 (2C, CArt), 20.3 (1C, CArt), 13.3 (CArt). HRMS (ESI+): calcd. for C28H38AuN2O5 m/z = 679.2452, found 679.2446.
ComplexAu(3-Quin)Cl (29) was obtained as a byproduct from the purification by column chromatography of Aubis(3-Quin) (8 mg). Anal. Calcd. For C30H37AuClN3O5: C, 47.91; H, 4.96; N, 5.59. Found C, 47.85; H, 5.08; N, 5.49. 1H-NMR (400 MHz, CDCl3): δ 8.78 (d, J = 8.7 Hz, 1H, HQuin), 8.41 (d, J = 8.6 Hz, 1H, HQuin), 8.07 (d, J = 8.2 Hz, 1H, HQuin), 8.04 (d, J = 2.0 Hz, 1H, H4), 7.93 (dd, J = 8.2, 1.4 Hz, 1H, HQuin), 7.81 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H, HQuin), 7.64 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H, HQuin), 7.20 (d, J = 2.1 Hz, 1H, H5), 5.44 (s, 1H, HArt), 4.84 (d, J = 3.6 Hz, 1H, HArt), 4.48–4.44 (m, 2H, HCH2), 4.01–3.96 (m, 1H, HCH2), 3.56–3.50 (m, 1H, HCH2), 2.69 (m, 1H, HArt), 2.44–2.36 (m, 1H, HArt), 2.31–2.27 (m, 2H, HCH2), 2.09–2.03 (m, 1H, HArt), 1.93–1.85 (m, 2H, HArt), 1.79–1.71 (m, 2H, HArt), 1.55–1.45 (m, 2H, HArt), 1.46 (s, 3H, HArt), 1.41–1.26 (m, 2H, HArt), 0.99 (d, J = 6.3 Hz, 3H, HArt), 0.97 (d, J = 6.3 Hz, 3H, HArt), 0.94–0.90 (m, 1H, HArt). 13C NMR (101 MHz, CDCl3): δ 173.7 (1C, C2), 149.1 (1C, CQuin), 146.5 (1C, CQuin), 139.6 (1C, CQuin), 130.9 (1C, CQuin), 128.9 (1C, CQuin), 127.9 (1C, CQuin), 127.9 (1C, CQuin), 127.5 (1C, CQuin), 121.2 (1C, C5), 120.6 (1C, C4), 115.4 (CQuin), 104.2 (1C, CArt), 102.2 (1C, CArt), 88.0 (1C, CArt), 81.0 (1C, CArt), 64.8 (1C, CCH2), 52.5 (1C, CArt), 49.7 (1C, CCH2), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 31.3 (1C, CCH2), 30.9 (1C, CArt), 26.2 (1C, CArt), 24.7 (2C, CArt), 20.3 (1C, CArt), 13.3 (1C, CArt). HRMS (ESI+): calcd. for C30H37AuN3O5 m/z = 716.2399, found 716.2418.
3′-Benzyl-1′-[10β-(21-butoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L4-Bn (7)). To a stirred solution of DHA-C4 (109 mg, 0.26 mmol) in CH3CN (4 mL) heated at 70 °C, 1-benzylimidazole (41 mg, 0.26 mmol) was added and the reaction mixture was stirred 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (109 mg, 73% yield). Anal. Calcd. for C29H41BrN2O5: C, 60.31; H, 7.16; N, 4.85. Found C, 60.26; H, 7.07; N, 4.79. 1H-NMR (300 MHz, CDCl3): δ 11.19 (sl, 1H, H2), 7.50–7.43 (m, 5H, HBn), 7.23–7.02 (m, 2H, H4, H5), 5.62 (s, 2H, HBn), 5.38 (s, 1H, HArt), 5.17 (s, 2H, HCH2), 4.78 (d, J = 3.5 Hz, 1H, HArt), 4.52–4.41 (m, 4H, HCH2), 3.81 (t, J = 5.6 Hz, 1H, HCH2), 3.50 (d, J = 10.0 Hz, 2H, HCH2), 2.65 (s, 1H, HArt), 2.21–2.09 (m, 1H, HArt), 2.09–2.00 (m, 2H, HArt), 1.66–1.64 (m, 6H, HArt), 1.45 (s, 2H, HArt), 1.35 (sl, 1H, HArt), 1.25 (t, J = 7.0 Hz, 1H, HArt), 0.98 (d, J = 6.1 Hz, 3H, HArt), 0.96–0.94 (m, 1H, HArt), 0.91 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 137.3 (1C, C2), 129.7 (2C, CBn), 129.1 (2C, CBn), 128.6 (1C, CBn), 122.1 (1C, C4), 121.4 (1C, C5), 120.6 (1C, CBn), 102.1 (1C, CArt), 94.0 (1C, CArt), 87.9 (1C, CArt), 61.1 (1C, CArt), 56.5 (1C, CCH2), 53.6 (1C, CBn), 51.7 (1C, CArt), 50.0 (1C, CArt), 45.3 (1C, CArt), 41.2 (1C, CArt), 40.3 (1C, CArt), 34.5 (1C, CArt), 30.3 (1C, CArt), 30.0 (1C, CCH2), 29.5 (1C, CCH2), 28.3 (1C, CArt), 27.5 (1C, CArt), 20.5 (1C, CCH2), 20.0 (1C, CArt), 11.1 (1C, CArt). HRMS (ESI+): calcd. for C29H41N2O5 m/z = 497.3010, found 497.3007.
3′-Mesityl-1′-[10β-(21-butoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L4-Mes (8)). To a stirred solution of DHA-C4 (189 mg, 0.45 mmol) in CH3CN (4 mL) heated at 70 °C, 1-mesitylimidazole (142 mg, 0.76 mmol) was added and the reaction mixture was stirred for 3 days. The solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (168 mg, 62% yield). Anal. Calcd. for C31H45BrN2O5: C, 61.48; H, 7.49; N, 4.63. Found C, 62.21; H, 7.66; N, 4.36. 1H-NMR (300 MHz, CDCl3): δ 10.55 (t, J = 1.4 Hz, 1H, H2), 7.68 (t, J = 1.9 Hz, 1H, H4), 7.15 (t, J = 1.9 Hz, 1H, H5), 7.03 (s, 2H, HMes), 5.42 (s, 1H, HArt), 5.02 (s, 1H, HArt), 4.86 (d, J = 3.3 Hz, 2H, HCH2), 3.94 (dt, J = 9.7, 6.2 Hz, 1H, HCH2), 3.63 (dt, J = 9.7, 6.2 Hz, 1H, HCH2), 2.37 (s, 3H, HMes), 2.36–2.24 (m, 1H, HArt), 2.19 (s, 1H, HArt), 2.11 (s, 6H, HMes), 2.10–2.01 (m, 1H, HArt), 1.95–1.87 (m, 1H, HCH2), 1.80–1.75 (m, 2H, HCH2), 1.72-1.66 (m, 2H, HArt), 1.64–1.60 (m, 3H, HArt), 1.57–1.52 (m, 1H, HCH2), 1.50–1.43 (m, 1H, HArt), 1.42 (s, 3H, HArt), 1.40–1.36 (m, 1H, HArt), 1.31–1.26 (m, 1H, HArt), 1.18 (sl, 2H, HArt), 1.16, (sl, 1H, HArt), 1.10–1.01 (m, 1H, HArt), 1.00–0.94 (m, 3H, HArt), 0.93–0.87 (m, 1H, HArt). 13C NMR (101 MHz, CDCl3): δ 139.1 (1C, CMes), 138.9 (1C, C2), 136.7 (2C, CMes), 129.3 (2C, CMes), 127.5 (1C, CMes), 123.0 (1C, C4), 120.6 (1C, C5), 104.1 (1C, CArt), 102.2 (1C, CArt), 87.9 (1C, CArt), 81.1 (1C, CArt), 67.7 (1C, CCH2), 52.5 (1C, CArt), 50.3 (1C, CCH2), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 30.9 (1C, CArt), 27.4 (1C, CCH2), 26.2 (1C, CArt), 25.0 (1C, CArt), 24.5 (1C, CArt), 21.2 (1C, CCH2), 20.4 (1C, CArt), 17.6 (2C, CMes), 17.3 (1C, CMes), 13.2 (1C, CArt). HRMS (ESI+): calcd. for C31H45N2O5 m/z = 525.3328, found 525.3353.
3′-Quinolin-2-yl-1′-[10β-(21-butoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L4-Quin (9)). To a stirred solution of DHA-C4 (128 mg, 0.31 mmol) in CH3CN (3 mL) heated at 70 °C, 1-(quinolin-2-yl)-imidazole (78 mg, 0.40 mmol) was added and the reaction mixture was stirred for 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (111 mg, 58% yield). Anal. Calcd. for C31H40BrN3O5: C, 60.58; H, 6.56; N, 6.84. Found C, 60.45; H, 6.72; N, 6.75. 1H-NMR (300 MHz, CDCl3): δ 12.03 (s, 1H, H2), 8.69–8.63 (m, 1H, HQuin), 8.58–8.50 (m, 2H, HQuin, H4), 8.04 (d, J = 8.7 Hz, 1H, HQuin), 7.88–7.74 (m, 2H, HQuin, H5), 7.70–7.57 (m, 1H, HQuin), 7.57 (sl, 1H, HQuin), 5.38 (s, 1H, HArt), 4.78 (d, J = 3.7 Hz, 1H, HArt), 4.70 (t, J = 7.3 Hz, 2H, HCH2), 3.97–3.85 (m, 1H, HCH2), 3.49–3.47 (m, 1H, HCH2), 2.66–2.58 (m, 1H, HArt), 2.44–2.30 (m, 1H, HArt), 2.20–2.11 (m, 2H, HArt), 2.02–1.96 (m, 1H, HArt), 1.88–1.82 (m, 1H, HArt), 1.81–1.64 (m, 4H, HCH2), 1.42 (s, 2H, HArt), 1.38 (s, 3H, HArt), 1.28–1.25 (m, 1H, HArt), 1.21–1.20 (m, 1H, HArt), 0.97 (d, J = 6.4 Hz, 3H, HArt), 0.96–0.93 (m, 1H, HArt), 0.90 (d, J = 7.0, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 146.1 (1C, CQuin), 144.5 (1C, CQuin), 141.7 (1C, CQuin), 140.3 (1C, CQuin), 137.0 (1C, C2), 131.5 (1C, CQuin), 128.8 (1C, CQuin), 128.2 (1C, C4), 127.8 (1C, CQuin), 121.6 (1C, C5), 119.0 (1C, CQuin), 112.9 (1C, CQuin), 104.2 (1C, CArt), 102.3 (1C, CArt), 88.0 (1C, CArt), 81.1 (1C, CArt), 65.9 (1C, CCH2), 52.5 (1C, CArt), 50.4 (1C, CArt), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 30.9 (1C, CArt), 27.3 (1C, CCH2), 26.5 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 20.3 (1C, CArt), 15.3 (1C, CCH2), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C31H40N3O5 m/z = 534.2962, found 534.2976.
ComplexAubis(4-Bn) (20). Under a nitrogen atmosphere, K2CO3 (36 mg, 0.26 mmol) was added to L4-Bn (108 mg, 0.19 mmol) in dry CH3CN (4 mL) and heated at 60 °C under stirring. Then, Au(SMe2)Cl (25 mg, 0.09 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a white solid (100 mg, 98% yield). Anal. Calcd. for C58H80AuClN4O10: C, 56.84; H, 6.58; N, 4.57. Found C, 56.75; H, 6.46; N, 4.51. 1H-NMR (300 MHz, CDCl3): δ 7.35–7.31 (m, 5H, HBn), 7.26 (sl, 2H, H4, H5), 5.45 (sl, 2H, HBn), 5.36 (s, 1H, HArt), 5.32 (s, 1H, HCH2), 4.77–4.71 (m, 1H, HArt), 4.26 (t, J = 7.1 Hz, 2H, HCH2), 3.81 (dt, J = 9.9, 6.3 Hz, 1H, HCH2), 3.37 (dt, J = 9.9, 6.3 Hz, 2H, HCH2), 2.66–2.58 (m, 1H, HArt), 2.45–2.32 (m, 1H, HArt), 2.16–2.11 (m, 1H, HArt), 2.10–2.00 (m, 1H, HArt), 1.97–1.86 (m, 3H, HCH2, HArt), 1.78–1.68 (m, 2H, HArt), 1.65–1.54 (m, 2H, HArt), 1.44 (s, 3H, HArt), 1.34–1.24 (m, 2H, HArt), 0.96 (d, J = 5.8 Hz, 3H, HArt), 0.90 (d, J = 2.2 Hz, 1H, HArt), 0.87 (d, J = 2.5 Hz, 3H, HArt). 13C NMR (75 MHz, CDCl3): δ 183.6 (1C, C2), 135.7 (1C, CBn), 129.1 (2C, CBn), 128.6 (1C, CBn), 127.4 (2C, CBn), 122.4 (1C, C4), 121.8 (1C, C5), 104.2 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 81.0 (1C, CArt), 67.5 (1C, CArt), 54.8 (1C, CBn), 52.5 (1C, CArt), 51.3 (1C, CCH2), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 30.8 (1C, CArt), 29.7 (1C, CCH2), 28.2 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 22.3 (1C, CCH2), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C58H80AuN4O10 m/z = 1189.5534, found 1189.5468.
ComplexAubis(4-Mes) (21). Under a nitrogen atmosphere, K2CO3 (17 mg, 0.13 mmol) was added to L4-Mes (55 mg, 0.09 mmol) in dry CH3CN (4 mL). The mixture was then heated at 60 °C. After, Au(SMe2)Cl (15 mg, 0.05 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a white solid (55 mg, 99% yield). Anal. Calcd. for C62H88AuClN4O10: C, 58.10; H, 6.92; N, 4.37. Found C, 58.19; H, 6.90; N, 4.37. 1H-NMR (300 MHz, CDCl3): δ 7.68 (t, J = 1.7 Hz, 1H, H4), 6.97–6.94 (m, 3H, H5, HMes), 5.36 (s, 1H, HArt), 5.29 (s, 1H, HArt), 4.75 (d, J = 3.5 Hz, 1H, HArt), 4.10 (t, J = 6.9 Hz, 2H, HCH2), 3.79 (dt, J = 9.8, 6.3 Hz, 1H, HCH2), 3.34 (dt, J = 9.8, 6.4 Hz, 1H, HCH2), 2.67–2.60 (m, 1H, HArt), 2.38 (s, 6H, HMes), 2.09–1.99 (m, 2H, HArt), 1.87 (d, J = 2.3 Hz, 9H, HCH2, HArt), 1.75 (sl, 3H, HMes), 1.68–1.61 (m, 2H, HCH2), 1.43 (s, 3H, HArt), 0.97 (d, J = 5.8 Hz, 3H, HArt), 0.90 (d, J = 7.3 Hz, 4H, HArt). 13C NMR (101 MHz, CDCl3): δ 183.9 (1C, C2), 139.6 (1C, CMes), 134.9 (2C, CMes), 134.8 (1C, CMes), 129.2 (2C, CMes), 122.6 (1C, C4), 122.5 (1C, C5), 102.9 (1C, CArt), 102.7 (1C, CArt), 89.4 (1C, CArt), 81.8 (1C, CArt), 68.1 (1C, CCH2), 51.7 (1C, CArt), 46.7 (1C, CCH2), 40.2 (1C, CArt), 37.3 (1C, CArt), 36.5 (1C, CArt), 34.3 (1C, CArt), 31.7 (1C, CArt), 28.3 (1C, CCH2), 26.6 (1C, CArt), 26.0 (1C, CArt), 24.7 (1C, CArt), 21.2 (1C, CCH2), 20.0 (1C, CMes), 19.4 (1C, CArt), 17.6 (2C, CMes), 15.3 (1C, CArt). HRMS (ESI+): calcd. for C62H88AuN4O10 m/z = 1245.6166, found 1245.6188.
ComplexAubis(4-Quin) (22). Under a nitrogen atmosphere, K2CO3 (28 mg, 0.20 mmol) was added to L4-Quin (89 mg, 0.14 mmol) in dry CH3CN (4 mL). The stirred mixture was then heated at 60 °C. Then, Au(SMe2)Cl (30 mg, 0.10 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure to give a white solid (84 mg, 92% yield). Anal. Calcd. For C62H78AuClN6O10: C, 57.29; H, 6.05; N, 6.47. Found C, 57.35; H, 6.01; N, 6.57. 1H-NMR (400 MHz, CDCl3): δ 8.41–8.29 (m, 1H, HQuin), 8.20–8.14 (m, 1H, HQuin), 8.09–8.05 (m, 1H, H4), 7.90–7.85 (m, 1H, HQuin), 7.79–7.73 (m, 1H, HQuin), 7.71–7.64 (m, 1H, HQuin), 7.57–7.47 (m, 2H, H5, HQuin), 5.35–5.32 (m, 1H, HArt), 4.77–4.65 (m, 1H, HArt), 4.46–4.45 (m, 2H, HCH2), 3.93–3.91 (m, 1H, HCH2), 3.81–3.74 (m, 1H, HCH2), 3.29–3.35 (m, 2H, HCH2), 2.63–2.62 (m, 1H, HArt), 2.42–2.32 (m, 1H, HArt), 2.15–2.11 (m, 2H, HCH2), 2.07–1.96 (m, 1H, HArt), 1.91–1.82 (m, 1H, HArt), 1.74–1.66 (m, 2H, HArt), 1.64–1.55 (m, 1H, HArt), 1.43 (s, 1H, HArt), 1.34–1.25 (m, 1H, HArt), 1.25–1.21 (m, 3H, HArt), 1.20–1.98 (m, 1H, HArt), 1.22–1.16 (m, 1H, HArt), 0.95 (d, J = 6.2 Hz, 3H, HArt), 0.87–0.85 (m, 4H, HArt). 13C NMR (126 MHz, CDCl3): δ 181.9 (1C, C2), 149.2 (1C, CQuin), 146.3 (1C, CQuin), 139.8 (1C, CQuin), 131.0 (1C, CQuin), 128.5 (1C, CQuin), 127.9 (1C, CQuin), 127.7 (1C, CQuin), 127.5 (1C, CQuin), 122.4 (1C, C4), 121.6 (1C, C5), 116.1 (1C, CQuin), 104.1 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 81.0 (1C, CArt), 67.8 (1C, CCH2), 65.9 (1C, CCH2), 52.5 (C1, CArt), 52.3 (1C, CArt), 44.3 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.5 (1C, CArt), 30.8 (1C, CArt), 28.2 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 20.3 (1C, CArt), 15.3 (1C, CCH2), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C62H78AuN6O10 m/z = 1263.5439, found 1263.5468.
3′-Benzyl-1′-[10β-(22-pentoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L5-Bn (10)). To a stirred solution of DHA-C5 (103 mg, 0.24 mmol) in CH3CN (4 mL) heated at 70 °C, 1-benzylimidazole (34 mg, 0.21 mmol) was added and the reaction mixture was stirred 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (64 mg, 52% yield). Anal. Calcd. for C30H43BrN2O5: C, 60.91; H, 7.33; N, 4.74. Found C, 60.91; H, 7.45; N, 4.68. 1H-NMR (300 MHz, CDCl3): δ 10.73 (t, J = 1.6 Hz, 1H, H2), 7.54–7.46 (m, 2H, HBn, H4/H5), 7.41–7.35 (m, 5H, HBn, H4/H5), 5.63 (s, 2H, HBn), 5.35 (s, 1H, HArt), 4.75–4.71 (m, 1H, HArt), 4.32–4.28 (m, 2H, HCH2), 3.85–3.76 (m, 1H, HCH2), 3.38–3.30 (m, 1H, HCH2), 2.65–2.53 (m, 1H, HArt), 2.41–2.30 (m, 1H, HArt), 2.07–1.90 (m, 3H, HArt), 1.89–1.82 (m, 1H, HCH2), 1.78–1.68 (m, 3H, HCH2, HArt), 1.66–1.57 (m, 4H, HCH2, HArt), 1.41 (s, 3H, HArt), 1.35–1.10 (m, 3H, HArt), 0.95 (d, J = 6.1 Hz, 4H, HArt), 0.85 (d, J = 7.3 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 137.9 (1C, C2), 135.0 (1C, CBn), 129.6 (1C, CBn), 129.5 (2C, CBn), 129.1 (2C, CBn), 121.4 (1C, C4), 121.3 (1C, C5), 104.1 (1C, CArt), 102.1 (1C, CArt), 89.7 (1C, CArt), 81.1 (1C, CArt), 67.9 (1C, CCH2), 53.6 (1C, CBn), 52.6 (1C, CArt), 50.0 (1C, CArt), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 30.9 (1C, CCH2), 30.0 (1C, CArt), 29.3 (1C, CCH2), 29.0 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 22.2 (1C, CCH2), 20.4 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C30H43N2O5 m/z = 511,3172, found 511.3171.
3′-Mesityl-1′-[10β-(22-pentoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L5-Mes (11)). To a stirred solution of DHA-C5 (160 mg, 0.37 mmol) in CH3CN (4 mL) heated at 70 °C, 1-mesitylimidazole (51 mg, 0.27 mmol) was added and the reaction mixture was stirred for 3 days. The solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (101 mg, 60% yield). Anal. Calcd. for C32H47BrN2O5: C, 62.03; H, 7.65; N, 4.52. Found C, 62.15; H, 7.75; N, 4.62. 1H-NMR (400 MHz, CDCl3): δ 10.64 (t, J = 1.5 Hz, 1H, H2), 7.58 (t, J = 1.7 Hz, 1H, H4), 7.16 (t, J = 1.8 Hz, 1H, H5), 7.03 (sl, 2H, HMes), 5.40 (s, 1H, HArt), 4.87–4.71 (m, 3H, HArt, HCH2), 3.85 (dt, J = 9.8, 6.4 Hz, 1H, HCH2), 3.41 (dt, J = 9.8, 6.4 Hz, 1H, HCH2), 2.69–2.59 (m, 1H, HArt), 2.44–2.34 (m, 4H, HMes, HArt), 2.11 (s, 6H, HMes), 2.10–2.01 (m, 3H, HArt), 1.94–1.87 (m, 1H, HCH2), 1.76–1.74 (m, 2H, HCH2, HArt), 1.72–1.66 (m, 2H, HCH2), 1.64 (s, 2H, HCH2), 1.55–1.47 (m, 3H, HArt), 1.45 (s, 3H, HArt), 1.41–1.31 (m, 1H, HArt), 1.30–1.23 (m, 1H, HArt), 0.98 (d, J = 6.2 Hz, 3H, HArt), 0.94–0.92 (m, 1H, HArt), 0.90 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 141.5 (1C, CMes), 138.7 (1C, C2), 134.2 (2C, CMes), 130.6 (1C, CMes), 130.0 (2C, CMes), 122.9 (1C, C4), 122.0 (1C, C5), 104.1 (1C, CArt), 102.1 (1C, CArt), 88.0 (1C, CArt), 81.1 (1C, CArt), 68.0 (1C, CCH2), 52.6 (1C, CArt), 50.5 (1C, CCH2), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 30.9 (1C, CArt), 30.4 (1C, CCH2), 29.1 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 23.0 (1C, CCH2), 21.1 (1C, CArt), 20.4 (1C, CMes), 17.7 (2C, CMes), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C32H47N2O5 m/z = 539.3485, found 539.3490.
3′-Quinolin-2-yl-1′-[10β-(22-pentoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (L5-Quin (12)). To a stirred solution of DHA-C5 (142 mg, 0.33 mmol) in CH3CN (3 mL) heated at 70 °C, 1-(quinolin-2-yl)-imidazole (84 mg, 0.43 mmol) was added and the reaction mixture was stirred for 3 days. Then, the solvent was removed under reduced pressure and the crude product was dissolved in CH2Cl2 and precipitated with Et2O. This treatment was repeated three times to afford a white solid (136 mg, 66% yield). Anal. Calcd. for C32H42BrN3O5: C, 61.14; H, 6.73; N, 6.68. Found C, 61.18; H, 6.67; N, 6.69. 1H-NMR (300 MHz, CDCl3): δ 11.99 (s, 1H, H2), 8.67–8.64 (m, 1H, HQuin), 8.55–8.52 (m, 1H, HQuin), 8.34–8.31 (m, 1H, H4), 8.05–8.02 (m, 1H, HQuin), 7.95–7.90 (m, 1H, HQuin), 7.88–7.83 (m, 1H, HQuin), 7.84–7.77 (m, 1H, HQuin), 7.59–7.53 (m, 1H, H5), 5.39–5.36 (m, 1H, HArt), 4.78–4.75 (m, 1H, HArt), 4.66–4.61 (m, 2H, HCH2, HArt), 3.84–3.80 (m, 1H, HCH2), 3.69–3.65 (m, 1H, HCH2), 3.46–3.31 (m, 3H, HCH2), 2.69–2.52 (m, 1H, HArt), 2.44–2.29 (m, 2H, HArt), 2.19–2.08 (m, 2H, HArt), 1.93–1.78 (m, 2H, HArt), 1.75–1.67 (m, 4H, HCH2), 1.58–1.47 (m, 4H, HArt), 1.28–1.25 (m, 2H, HArt), 0.96 (d, J = 6.4 Hz, 3H, HArt), 0.95 (m, 1H, HArt), 0.93 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 146.1 (1C, CQuin), 144.5 (1C, CQuin), 141.6 (1C, CQuin), 136.8 (1C, C2), 131.5 (1C, CQuin), 129.0 (1C, CQuin), 128.8 (1C, CQuin), 128.3 (1C, CQuin), 128.1 (1C, CQuin), 122.2 (1C, C4), 119.0 (1C, C5), 112.8 (1C, CQuin), 104.3 (1C, CArt), 102.1 (1C, CArt), 87.9 (1C, CArt), 81.1 (1C, CArt), 67.9 (1C, CCH2), 51.0 (1C, CArt), 50.4 (1C, CArt), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.4 (1C, CArt), 31.1 (1C, CCH2), 30.0 (1C, CArt), 29.5 (1C, CCH2), 26.2 (1C, CArt), 26.2 (1C, CCH2), 23.1 (1C, CArt), 22.2 (1C, CCH2), 20.5 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C32H42N3O5 m/z = 548.3119, found 548.3118.
ComplexAubis(5-Bn) (24). Under a nitrogen atmosphere, K2CO3 (20 mg, 0.14 mmol) was added to L5-Bn (60 mg, 0.10 mmol) in dry CH3CN (4 mL) and heated at 60 °C under stirring. Then, Au(SMe2)Cl (15 mg, 0.05 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a white solid (28 mg, 45% yield). Anal. Calcd. for C60H84AuClN4O10: C, 57.48; H, 6.75; N, 4.47. Found C, 57.58; H, 6.89; N, 4.32. 1H-NMR (300 MHz, CDCl3): δ 7.34–7.32 (m, 4H, HBn), 7.26–7.25 (m, 3H, H4, H5), 5.42 (s, 2H, HBn), 5.34 (s, 1H, HArt), 4.74 (m, 1H, HArt), 4.22–4.17 (m, 2H, HCH2), 3.81–3.74 (m, 1H, HCH2), 3.36–3.28 (m, 1H, HCH2), 2.66–2.56 (m, 1H, HArt), 2.42–2.32 (m, 1H, HArt), 2.10–2.00 (m, 1H, HArt), 1.96–1.82 (m, 3H, HCH2), 1.76–1.68 (m, 3H, HArt), 1.66–1.53 (m, 3H, HCH2), 1.50–1.45 (s, 1H, HArt), 1.40–1.18 (m, 6H, HArt), 0.96–0.94 (m, 3H, HArt), 0.91 (d, J = 7.4 Hz, 2H, HArt), 0.86 (d, J = 7.3 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 183.8 (1C, C2), 135.7 (1C, CBn), 129.1 (2C, CBn), 128.6 (1C, CBn), 127.4 (2C, CBn), 122.3 (1C, C4), 122.1 (1C, C5), 104.1 (1C, CArt), 101.9 (1C, CArt), 87.9 (1C, CArt), 81.1 (1C, CArt), 67.9 (1C, CCH2), 54.8 (1C, CBn), 52.5 (1C, CArt), 51.5 (1C, CCH2), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 31.2 (1C, CCH2), 30.9 (1C, CArt), 29.2 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 23.3 (1C, CCH2), 20.4 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C60H84AuN4O10 m/z = 1217.5847, found 1217.5889.
ComplexAubis(5-Mes) (25). Under a nitrogen atmosphere, K2CO3 (36 mg, 0.26 mmol) was added to L5-Mes (101 mg, 0.16 mmol) in dry CH3CN (4 mL). The mixture was then heated at 60 °C. After, Au(SMe2)Cl (27 mg, 0.09 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure. The complex was purified by flash chromatography on silica with CH2Cl2-MeOH as eluent (100/0 to 100/10) to give a white solid (78 mg, 74% yield). Anal. Calcd. for C64H92AuClN4O10: C, 58.69; H, 7.08; N, 4.28. Found C, 58.78; H, 7.02; N, 4.31. 1H-NMR (300 MHz, CDCl3): δ 7.66 (d, J = 1.8 Hz, 1H, H4), 6.97 (s, 2H, HMes), 6.93 (d, J = 1.8 Hz, 1H, H5), 5.40 (s, 1H, HArt), 4.78 (d, J = 3.3 Hz, 1H, HArt), 4.11 (t, J = 6.9 Hz, 2H, HCH2), 3.80 (dt, J = 9.7, 6.9 Hz, 1H, HCH2), 3.34 (dt, J = 9.7, 6.9 Hz, 1H, HCH2), 2.65–2.63 (m, 1H, HArt), 2.40 (s, 3H, HMes), 2.35 (m, 1H, HArt), 2.10–2.00 (m, 2H, HArt), 1.96–1.90 (m, 1H, HArt), 1.87 (d, J = 3.0 Hz, 6H, HMes), 1.82–1.73 (m, 6H, HCH2), 1.72–1.60 (m, 3H, HArt), 1.56–1.49 (m, 1H, HArt), 1.45 (s, 4H, HArt), 1.33–1.26 (m, 1H, HArt), 0.98 (d, J = 6.0 Hz, 3H, HArt), 0.95–0.92 (m, 1H, HArt), 0.90 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (101 MHz, CDCl3): δ 183.8 (1C, C2), 139.6 (1C, CMes), 134.8 (2C, CMes), 129.4 (1C, CMes), 129.2 (2C, CMes), 122.7 (1C, C4), 122.5 (1C, C5), 104.1 (1C, CArt), 102.0 (1C, CArt), 87.9 (1C, CArt), 81.1 (1C, CArt), 68.1 (1C, CCH2), 52.5 (1C, CArt), 51.1 (1C, CCH2), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 31.1 (1C, CCH2), 30.9 (1C, CArt), 29.3 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 23.0 (1C, CCH2), 21.2 (1C, CArt), 20.4 (2C, CMes), 17.7 (1C, CMes), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C64H92AuN4O10 m/z = 1273.6473, found 1273.6495.
ComplexAubis(5-Quin) (26). Under a nitrogen atmosphere, K2CO3 (37 mg, 0.27 mmol) was added to L5-Quin (121 mg, 0.19 mmol) in dry CH3CN (4 mL). The stirred mixture was then heated at 60 °C. Then, Au(SMe2)Cl (34 mg, 0.12 mmol) was added and the mixture was stirred for 10 h. After cooling to room temperature, the solution was filtered through a pad of celite and the solvent removed under reduced pressure to give a white solid (59 mg, 47% yield). Anal. Calcd. For C64H82AuClN6O10: C, 59.48; H, 6.40; N, 6.50. Found C, 59.45; H, 6.53; N, 6.45. 1H-NMR (300 MHz, CDCl3): δ 8.36 (m, 1H, HQuin), 8.18 (m, 1H, HQuin), 8.04 (m, 1H, H4), 7.89 (m, 1H, HQuin), 7.77 (m, 1H, HQuin), 7.71–7.65 (m, 1H, HQuin), 7.54 (m, 1H, H5), 7.51–7.48 (m, 1H, HQuin), 5.35–5.32 (m, 1H, HArt), 4.71 (m, 1H, HArt), 4.49–4.45 (m, 2H, HArt), 3.73–3.70 (m, 1H, HCH2), 3.53–3.46 (m, 3H, HCH2), 3.30–3.22 (m, 1H, HCH2), 2.63–2.57 (m, 1H, HArt), 2.42–2.32 (m, 1H, HArt), 2.13 (s, 1H, HArt), 2.02 (sl, 2H, HArt), 1.97–1.92 (m, 2H, HArt), 1.75–1.69 (m, 1H, HCH2), 1.61–1.59 (m, 1H, HCH2), 1.54–1.49 (m, 2H, HCH2), 1.44 (s, 3H, HArt), 1.34–1.27 (m, 3H, HArt), 0.94 (d, J = 5.9 Hz, 3H, HArt), 0.87 (m, 1H, HArt), 0.85 (d, J = 7.4 Hz, 3H, HArt). 13C NMR (75 MHz, CDCl3): δ 181.8 (1C, C2), 149.2 (1C, CQuin), 146.3 (1C, CQuin), 139.8 (1C, CQuin), 130.9 (1C, CQuin), 128.5 (1C, CQuin), 127.9 (1C, CQuin), 127.7 (1C, CQuin), 127.5 (1C, CQuin), 122.5 (1C, C4), 121.5 (1C, C5), 116.1 (1C, CQuin), 104.1 (1C, CArt), 101.9 (1C, CArt), 88.0 (1C, CArt), 81.0 (1C, CArt), 67.9 (1C, CCH2), 52.5 (C1, CCH2), 52.5 (1C, CArt), 50.6 (1C, CCH2), 44.4 (1C, CArt), 37.5 (1C, CArt), 36.4 (1C, CArt), 34.6 (1C, CArt), 31.0 (1C, CCH2), 30.8 (1C, CArt), 29.1 (1C, CCH2), 26.2 (1C, CArt), 24.7 (1C, CArt), 24.5 (1C, CArt), 20.4 (1C, CArt), 13.1 (1C, CArt). HRMS (ESI+): calcd. for C64H82AuN6O10 m/z = 1291.5758, found 1291.5785.

3.2. Biology

3.2.1. Parasite Cultures

The Plasmodium falciparum F32-ART and F32-TEM parasite lines, resistant and sensitive to artemisinins respectively [9,15], were cultured in vitro in type O human erythrocytes (Etablissement Français du sang (EFS), Toulouse, France), diluted to 2% hematocrit, in RPMI-1640 medium (GIBCO, Illkirch, France) and supplemented with 5% Human Serum AB (EFS, Toulouse, France) at 37 °C and 5% CO2 [33]. Every other day and before each experiment, P. falciparum F32-ART and F32-TEM parasites were synchronized at ring stage using 5% D-sorbitol solution [34].

3.2.2. Evaluation of Antiplasmodial Activity

In vitro antiplasmodial activities of the synthesized hybrid molecules were evaluated against the P. falciparum strain F32-TEM (corresponding to the parental strain F32-Tanzania). Each molecule was tested at least in three independent experiments (except Aubis(5-Bn), tested twice) by a SYBR Green Fluorescence assay [33] but also at least once with the standard chemosensitivity assay recommended by the WHO and based on the incorporation of [3H] hypoxanthine [33].
For the SYBR Green Fluorescence assay, ring stage parasites were treated with the drugs for 48 h. Then, the pellets were washed twice with PBS and frozen at −20 °C. Thawed plates were incubated for 2 h at room temperature with the SYBR Green (Thermo-Fisher, Illkirch, France) lysis buffer (20 mm Tris base pH 7.5, 5 mm EDTA, 0.008% w/v saponin, 0.08% w/v Triton X-100). The plates were then read using a fluorescence plate reader (FLx800, BioTek, Illkirch, France) at an excitation wavelength of 485 nm and 535 nm for the emission wavelength. The IC50 values (concentration inhibiting 50% of the parasite’s growth) were determined using GraphPad Prism software 7 (GraphPad Software, San Diego, CA, USA).
For [3H] hypoxanthine assay, ring stage parasites were incubated with the drug dilutions for 24 h, then, [3H] hypoxanthine (50 μL/0.25 μCi; Perkin-Elmer, Courtaboeuf, France) was added for another 24 h period. After that, plates were frozen at −20 °C. The next step is to thaw the plates and to collect the nucleic acids. Tritium incorporation was then determined thanks to a β-counter (Perkin-Elmer, Courtaboeuf, France).
The antiplasmodial activities reported in Table 1 correspond thus to the mean of IC50 values from at least 4 independent experiments acquired by the two methods, SYBR Green and radioactivity.

3.2.3. Evaluation of the Cytotoxicity

The most active compounds were tested for their cytotoxicity using the Vero cell line (monkey epithelial cell line), according to a previously described method [35] with some modifications. The cells were cultured in MEM medium (Dutscher, Brumath, France) supplemented with 10% fetal bovine serum (Dutscher), 0.7 mM glutamine and 100 μg/mL gentamicin.
The cells were seeded at 104 cells per well in a 96-well plates and incubated during 24 h. Then, cells were incubated for additional 48 h with the drugs. Cell proliferation was measured with MTT (1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan, Sigma, Saint-Quentin Fallavier, France) which is added to each well for 1 h at 37° C and 5% CO2. Subsequently, DMSO was added to the wells containing the cells and MTT to dissolve the formed crystals. The plates were then read to determine the absorbance at wavelength of 540 nm (µQuant, BioTek, Illkirch, France). Cell proliferation was calculated from at least three independent experiments using GraphPad Prism software 7 (GraphPad Software, San Diego, CA, USA). The cytotoxic/antiplasmodial activity ratio corresponds to the selectivity index.

3.2.4. Recrudescence Assay

P. falciparum strains F32-ART and F32-TEM, synchronized at ring stage parasites at 3% parasitemia and 2% hematocrit have undergone a 48 h-treatment with the drugs to be tested. The parasites were then washed with RPMI-1640 medium and re-cultivated in drug-free culture conditions with 10% human serum. The parasitemia was then monitored daily to determine the time required for each parasite culture to recover the initial parasitemia of 3%. If no parasites were seen up to 30 days, the parasites were considered as “not recrudescent” [9,15]. The drug doses were chosen in order to discriminate the phenotype response between the artemisinin-resistant and the -sensitive strains. A range from 1-fold to >100-fold the antiplasmodial IC50 value previously found has been tested to determine the most appropriate drug dose to use in this recrudescence assay.

4. Conclusions

Three original families of gold(I) NHCs complexes incorporating a covalently attached DHA derivative were synthetized and fully characterized. All the proligands and complexes were tested for their antiplasmodial potency on the P. falciparum strains, F32-TEM artemisinin-sensitive and F32-ART artemisinin-resistant. Among the 29 compounds tested, ten gold(I) complexes have shown high antiplasmodial activities, with IC50 values less than 50 nM and very low cytotoxicity, with selectivity indexes up to 294. However, even though a simple gold(I) bis(NHC) had shown in a previous work [20] no cross-resistance with artemisinins, the presence of this metal could not prevent cross-resistance in the hybrid gold(I)-DHA complexes Aubis(3-Me), Aubis(4-Me) and Aubis(5-Me) tested. These data confirm that the presence of an endoperoxide moiety whatever the structure and the other parts of the hybrid molecules tested leads to artemisinins cross-resistance. Therefore, these findings raise concerns about the potential development of new artemisinin derivatives and more broadly endoperoxide-based antiplasmodial drugs even if they include a moiety metabolically active on biochemical pathways involved in the quiescence state.

Supplementary Materials

Supplementary File 1

Author Contributions

Conceptualization, C.H. and H.G.; methodology, C.H.; synthesis, purification and characterization of the hybrid molecules, G.B. and Á.F.Á.; in vitro antimalarial and cytotoxic activities experiments, M.O.; in vitro cross-resistance assays, M.O.; writing-review and editing, C.H., H.G., M.O., F.B.-V. and J.-M.A.; supervision, C.H., H.G., F.B.-V. and J.-M.A.; funding acquisition, F.B.-V. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported in part by the French “Agence Nationale de la Recherche” (ANR grant INMAR ANR16 CE35 0003) and the “Centre National de la Recherche Scientifique”.

Conflicts of Interest

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study, analyses or interpretation of data, in the writing of the manuscript, and in the decision to publish the results.

References

  1. World Health Organisation. World Malaria Report; WHO: Geneva, Suisse, 2018; ISBN 9789241565653. [Google Scholar]
  2. Wongsrichanalai, C.; Meshnick, S.R. Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border. Emerg. Infect. Dis. J. 2008, 14, 716. [Google Scholar] [CrossRef] [PubMed]
  3. Amato, R.; Lim, P.; Miotto, O.; Amaratunga, C.; Dek, D.; Pearson, R.D.; Almagro-Garcia, J.; Neal, A.T.; Sreng, S.; Suon, S.; et al. Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: A genotype–phenotype association study. Lancet Infect. Dis. 2017, 17, 164–173. [Google Scholar] [CrossRef] [Green Version]
  4. Witkowski, B.; Duru, V.; Khim, N.; Ross, L.S.; Saintpierre, B.; Beghain, J.; Chy, S.; Kim, S.; Ke, S.; Kloeung, N.; et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: A phenotype–genotype association study. Lancet Infect. Dis. 2017, 17, 174–183. [Google Scholar] [CrossRef] [Green Version]
  5. Ouji, M.; Augereau, J.M.; Paloque, L.; Benoit-Vical, F. Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination. Parasite 2018, 25, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Walsh, J.J.; Coughlan, D.; Heneghan, N.; Gaynor, C.; Angus, B. A novel artemisinin-quinine hybrid with potent antimalarial activity. Bioorg. Med. Chem. Lett. 2007, 17, 3599–3602. [Google Scholar] [CrossRef]
  7. Fröhlich, T.; Karagöz, A.Ç.; Reiter, C.; Tsogoeva, S.B. Artemisinin-derived dimers: Potent antimalarial and anticancer agents. J. Med. Chem. 2006, 59, 7360–7388. [Google Scholar] [CrossRef]
  8. Elsohly, M.A.; Gul, W.; Khan, S.L.; Tekwani, B.L. New orally active artemisinin dimer antimalarials. World J. Tradit. Chin. Med. 2017, 3, 3. [Google Scholar] [CrossRef]
  9. Witkowski, B.; Lelièvre, J.; Barragán, M.J.L.; Laurent, V.; Su, X.Z.; Berry, A.; Benoit-Vical, F. Increased tolerance to artemisinin in plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 2010, 54, 1872–1877. [Google Scholar] [CrossRef] [Green Version]
  10. Ariey, F.; Witkowski, B.; Amaratunga, C.; Beghain, J.; Langlois, A.C.; Khim, N.; Kim, S.; Duru, V.; Bouchier, C.; Ma, L.; et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505, 50–55. [Google Scholar] [CrossRef]
  11. Teuscher, F.; Gatton, M.L.; Chen, N.; Peters, J.; Kyle, D.E.; Cheng, Q. Artemisinin-Induced Dormancy in Plasmodium falciparum: Duration, Recovery Rates, and Implications in Treatment Failure. J. Infect. Dis. 2010, 202, 1362–1368. [Google Scholar] [CrossRef] [Green Version]
  12. Intharabut, B.; Kingston, H.W.; Srinamon, K.; Ashley, E.A.; Imwong, M.; Dhorda, M.; Woodrow, C.; Stepniewska, K.; Silamut, K.; Day, N.P.J.; et al. Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria. J. Infect. Dis. 2019, 219, 1483–1489. [Google Scholar] [CrossRef] [PubMed]
  13. Paloque, L.; Ramadani, A.P.; Mercereau-Puijalon, O.; Augereau, J.M.; Benoit-Vical, F. Plasmodium falciparum: Multifaceted resistance to artemisinins. Malar. J. 2016, 15, 149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Chen, N.; LaCrue, A.N.; Teuscher, F.; Waters, N.C.; Gatton, M.L.; Kyle, D.E.; Cheng, Q. Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of plasmodium falciparum. Antimicrob. Agents Chemother. 2014, 58, 4773–4781. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Ménard, S.; Haddou, T.B.; Ramadani, A.P.; Ariey, F.; Iriart, X.; Beghain, J.; Bouchier, C.; Witkowski, B.; Berry, A.; Mercereau-Puijalon, O.; et al. Induction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressure. Emerg. Infect. Dis. 2015, 21, 1733–1741. [Google Scholar] [CrossRef] [PubMed]
  16. Peatey, C.L.; Chavchich, M.; Chen, N.; Gresty, K.J.; Gray, K.A.; Gatton, M.L.; Waters, N.C.; Cheng, Q. Mitochondrial Membrane Potential in a Small Subset of Artemisinin-Induced Dormant Plasmodium falciparum Parasites in vitro. J. Infect. Dis. 2015, 212, 426–434. [Google Scholar] [CrossRef] [Green Version]
  17. Krnajski, Z.; Gilberger, T.W.; Walter, R.D.; Cowman, A.F.; Müller, S. Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages. J. Biol. Chem. 2002, 277, 25970–25975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Hemmert, C.; Fabié, A.; Fabre, A.; Benoit-Vical, F.; Gornitzka, H. Synthesis, structures, and antimalarial activities of some silver(I), gold(I) and gold(III) complexes involving N-heterocyclic carbene ligands. Eur. J. Med. Chem. 2013, 60, 64–75. [Google Scholar] [CrossRef]
  19. Hemmert, C.; Ramadani, A.P.; Boselli, L.; Fernández Álvarez, Á.; Paloque, L.; Augereau, J.-M.; Gornitzka, H.; Benoit-Vical, F. Antiplasmodial activities of gold(I) complexes involving functionalized N-heterocyclic carbenes. Bioorg. Med. Chem. 2016, 24, 3075–3082. [Google Scholar] [CrossRef]
  20. Ouji, M.; Delmas, S.B.; Álvarez, Á.F.; Augereau, J.-M.; Valentin, A.; Hemmert, C.; Gornitzka, H.; Benoit-Vical, F. Design, Synthesis and Efficacy of Hybrid Triclosan-gold Based Molecules on Artemisinin-resistant Plasmodium falciparum and Leishmania infantum Parasites. ChemistrySelect 2020, 5, 619–625. [Google Scholar] [CrossRef]
  21. Paloque, L.; Hemmert, C.; Valentin, A.; Gornitzka, H. Synthesis, characterization, and antileishmanial activities of gold(I) complexes involving quinoline functionalized N-heterocyclic carbenes. Eur. J. Med. Chem. 2015, 94, 22–29. [Google Scholar] [CrossRef]
  22. Zhang, C.; Bourgeade Delmas, S.; Fernández Álvarez, Á.; Valentin, A.; Hemmert, C.; Gornitzka, H. Synthesis, characterization, and antileishmanial activity of neutral N-heterocyclic carbenes gold(I) complexes. Eur. J. Med. Chem. 2018, 143, 1635–1643. [Google Scholar] [CrossRef] [PubMed]
  23. Boselli, L.; Ader, I.; Carraz, M.; Hemmert, C.; Cuvillier, O.; Gornitzka, H. Synthesis, structures, and selective toxicity to cancer cells of gold(I) complexes involving N-heterocyclic carbene ligands. Eur. J. Med. Chem. 2014, 85, 87–94. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, C.; Hemmert, C.; Gornitzka, H.; Cuvillier, O.; Zhang, M.; Sun, R.W.-Y. Cationic and Neutral N-Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI-60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species Formation. ChemMedChem 2018, 13, 1218–1229. [Google Scholar] [CrossRef] [PubMed]
  25. Zhang, C.; Maddelein, M.L.; Wai-Yin Sun, R.; Gornitzka, H.; Cuvillier, O.; Hemmert, C. Pharmacomodulation on Gold-NHC complexes for anticancer applications—Is lipophilicity the key point? Eur. J. Med. Chem. 2018, 157, 320–332. [Google Scholar] [CrossRef] [PubMed]
  26. Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 2009, 253, 1692–1707. [Google Scholar] [CrossRef]
  27. Haynes, R.K.; Chan, H.-W.; Ho, W.-Y.; Ko, C.K.-F.; Gerena, L.; Kyle, D.E.; Peters, W.; Robinson, B.L. Convenient Access Both to Highly Antimalaria-Active 10-Arylaminoartemisinins, and to 10-Alkyl Ethers Including Artemether, Arteether, and Artelinate. ChemBioChem 2005, 6, 659–667. [Google Scholar] [CrossRef] [PubMed]
  28. Zhang, C.; Fortin, P.-Y.; Barnoin, G.; Qin, X.; Wang, X.; Fernandez Alvarez, A.; Bijani, C.; Maddelein, M.-L.; Hemmert, C.; Cuvillier, O.; et al. Artemisinin-Derivative-NHC-gold(I)-Hybrid with Enhanced Cytotoxic Activity Through Inhibiting NRF2 Transcriptional Activity. Angew. Chem. Int. Ed. 2020. [Google Scholar] [CrossRef]
  29. Strassner, T.; Unger, Y.; Zeller, A. Use of Pt- and Pd-bis- and tetracarbon complexes with bridged carbon ligands in OLEDs. 20090326237, 31 December 2009. [Google Scholar]
  30. Witkowski, B.; Khim, N.; Chim, P.; Kim, S.; Ke, S.; Kloeung, N.; Chy, S.; Duong, S.; Leang, R.; Ringwald, P.; et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob. Agents Chemother. 2013, 57, 914–923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Paloque, L.; Witkowski, B.; Lelièvre, J.; Ouji, M.; Ben Haddou, T.; Ariey, F.; Robert, A.; Augereau, J.M.; Ménard, D.; Meunier, B.; et al. Endoperoxide-based compounds: Cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism. J. Antimicrob. Chemother. 2018, 73, 395–403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Straimer, J.; Gnädig, N.F.; Stokes, B.H.; Ehrenberger, M.; Crane, A.A.; Fidock, D.A. Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. MBio 2017, 8, e00172-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Desjardins, R.E.; Canfield, C.J.; Haynes, J.D.; Chulay, J.D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 1979, 16, 710–718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Lambros, C.; Vanderberg, J.P. Synchronization of Plasmodium falciparum Erythrocytic Stages in Culture. J. Parasitol. 1979, 65, 418. [Google Scholar] [CrossRef] [PubMed]
  35. Tengchaisri, T.; Chawengkirttikul, R.; Rachaphaew, N.; Reutrakul, V.; Sangsuwan, R.; Sirisinha, S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998, 133, 169–175. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 25 02817 sch001 550
Scheme 1. Synthesis of proligands Ln-R (1–13) and gold(I) complexes Aubis(n-R) and Au(n-R)Cl complexes (14–29).
Scheme 1. Synthesis of proligands Ln-R (1–13) and gold(I) complexes Aubis(n-R) and Au(n-R)Cl complexes (14–29).
Molecules 25 02817 sch001

EntryProligandnRYield (%)EntryComplexnRYield (%)
1 *L3-Me3Me6514 *,§Aubis(3-Me)3Me84
2L3-iPr3iPr4715Aubis(3-iPr)3iPr83
3L3-Bn3Bn8716Aubis(3-Bn)3Bn65
4L3-Mes3Mes7617Aubis(3-Mes)3Mes52
5L3-Quin3Quin8418Aubis(3-Quin)3Quin86
6*L4-Me4Me9819*Aubis(4-Me)4Me80
7L4-Bn4Bn7320Aubis(4-Bn)4Bn92
8L4-Mes4Mes6221Aubis(4-Mes)4Mes89
9L4-Quin4Quin5822Aubis(4-Quin)4Quin92
10*L5-Me5Me3523*Aubis(5-Me)5Me32
11L5-Bn5Bn5224Aubis(5-Bn)5Bn45
12L5-Mes5Mes6025Aubis(5-Mes)5Mes74
13L5-Quin5Quin6626Aubis(5-Quin)5Quin47
27Au(3-iPr)Cl3Me42
28Au(3-Bn)Cl3Bn81
29Au(3-Quin)Cl3Quin-
* From reference [25]. § Complex Aubis(3-Me) (14) was synthetized according to the transmetalation route [25].
Table
Table 1. Antimalarial and cytotoxic activities of proligands and gold(I) complexes.
Table 1. Antimalarial and cytotoxic activities of proligands and gold(I) complexes.
EntryCompounds Antiplasmodial Activity on P. falciparum IC50 ± SEM (nM)Cytotoxicity on Vero CellsIC50 ± SEM (nM)Selectivity Index Vero Cells/P. falciparum
1Auranofin 1.5 × 103 ± 0.1 × 103
2Artemisinin 18 ± 2130 × 1037 000
3Artemether 6.1 ± 1214 × 103 ± 29.10335 000
4DHA-C3 8.5 ± 32.5 × 103 ± 0.1 × 103294
5L3-Me1935 ± 117--
6L3-iPr2335 ± 28--
7L3-Bn3351 ± 56--
8L3-Mes4655 ± 53--
9L3-Quin5330 ± 69--
10Aubis(3-Me)1435 ± 85 × 103 ± 1.5 × 103143
11Aubis(3-iPr)1513 ± 50.7 × 103 ± 0.2 × 10354
12Au(3-iPr)Cl2745 ± 88 × 103 ± 103178
13Aubis(3-Bn)1622 ± 30.3 × 103 ± 0.005 × 10314
14Au(3-Bn)Cl28104 ± 248 × 103 ± 2.3 × 10377
15Aubis(3-Mes)1761 ± 370.5 × 103 ± 0.1 × 1038
16Aubis(3-Quin)1823 ± 81.2 × 103 ± 0.5 × 10352
17Au(3-Quin)Cl2990 ± 9--
18L4-Me6840 ± 64--
19L4-Bn7326 ± 44--
20L4-Mes8219 ± 18--
21L4-Quin9330 ± 37--
22Aubis(4-Me)1913 ± 30.8 × 103 ± 0.2 × 10362
23Aubis(4-Bn)2040 ± 210.7 × 103 ± 0.2 × 10318
24Aubis(4-Mes)2138 ± 30.7 × 103 ± 0.1 × 10318
25Aubis(4-Quin)2283 ± 31--
26L5-Me10172 ± 22--
27L5-Bn1198 ± 26103 ± 0.1 × 10310
28L5-Mes1298 ± 2425 × 103 ± 10 × 103255
29L5-Quin13226 ± 29--
30Aubis(5-Me)239 ± 0.9103 ± 0.5 × 103111
31Aubis(5-Bn)2472 ± 140.6 × 103 ± 0.1 × 1038
32Aubis(5-Mes)25100 ± 12--
33Aubis(5-Quin)2638 ± 92 × 103 ± 0.7 × 10353
Values of the 50% inhibitory concentration (IC50) against Plasmodium falciparum were obtained using both SYBR Green and radioactivity assays. Cytotoxic activities of the compounds were determined against the Vero cell line. The antiplasmodial control drugs, artemether and artemisinin were routinely tested.
Table
Table 2. Recrudescence capacity of Plasmodium falciparum F32-ART and F32-TEM strains after 48h-drug exposure.
Table 2. Recrudescence capacity of Plasmodium falciparum F32-ART and F32-TEM strains after 48h-drug exposure.
ComplexesDosesNumber of ExperimentsMedian (range) Recrudescence DaysMean ± SEM Difference of Recrudescence Days between F32-TEM and F32-ART
F32-ARTF32-TEM
Artemisinin18 µM69.5 (6–17)18.5 (17–>30)9.7 ± 0.3
Aubis(4-Me) (14)100 nM1561
500 nM212.5 (11–14)>30>17.5 ± 1.5
1 µM1163014
Aubis(5-Me) (19)100 nM16159
500 nM29.5 (8–11)>25.5 (21–>30)>16
1 µM193021
Aubis(3-Me) (23)200 nM37 (7–13)14 (11–16)4.6 ± 1.2
500 nM182416
Synchronized ring-stage parasites have undergone 48 h of drug treatment. After that, cultures were washed and parasitemia was monitored during 30 days or until reaching the initial parasitemia, defined as the recrudescence day. If no parasites were observed at the end of the experiment, the culture was classified as showing no recrudescence, and the recrudescence day was noted as >30.

Share and Cite

MDPI and ACS Style

Ouji, M.; Barnoin, G.; Fernández Álvarez, Á.; Augereau, J.-M.; Hemmert, C.; Benoit-Vical, F.; Gornitzka, H. Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites. Molecules 2020, 25, 2817. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules25122817

AMA Style

Ouji M, Barnoin G, Fernández Álvarez Á, Augereau J-M, Hemmert C, Benoit-Vical F, Gornitzka H. Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites. Molecules. 2020; 25(12):2817. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules25122817

Chicago/Turabian Style

Ouji, Manel, Guillaume Barnoin, Álvaro Fernández Álvarez, Jean-Michel Augereau, Catherine Hemmert, Françoise Benoit-Vical, and Heinz Gornitzka. 2020. "Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites" Molecules 25, no. 12: 2817. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules25122817

Article Metrics

Back to TopTop